HK1255203A1 - 用於治療hcv的固體藥物組合物 - Google Patents

用於治療hcv的固體藥物組合物

Info

Publication number
HK1255203A1
HK1255203A1 HK18114330.0A HK18114330A HK1255203A1 HK 1255203 A1 HK1255203 A1 HK 1255203A1 HK 18114330 A HK18114330 A HK 18114330A HK 1255203 A1 HK1255203 A1 HK 1255203A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
solid pharmaceutical
treating hcv
hcv
treating
Prior art date
Application number
HK18114330.0A
Other languages
English (en)
Inventor
Katharin Asmus
Yi Gao
Colleen Garrett
Harald Hach
Adivaraha Jayasankar
Samuel Kyeremateng
Ute Lander
Thomas Mueller
Marius Naris
Constanze Obermiller
Regina Reul
Katrin Schneider
Nancy Sever
Michael Siimon
Benedikt Steitz
Ping Tong
Ulrich Westedt
Donghua Zhu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/192,211 external-priority patent/US20160375087A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1255203A1 publication Critical patent/HK1255203A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18114330.0A 2015-07-17 2018-11-08 用於治療hcv的固體藥物組合物 HK1255203A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
US15/192,211 US20160375087A1 (en) 2015-06-26 2016-06-24 Solid Pharmaceutical Compositions for Treating HCV
PCT/US2016/042806 WO2017015211A1 (en) 2015-07-17 2016-07-18 Solid pharmaceutical compositions for treating hcv

Publications (1)

Publication Number Publication Date
HK1255203A1 true HK1255203A1 (zh) 2019-08-09

Family

ID=57834557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114330.0A HK1255203A1 (zh) 2015-07-17 2018-11-08 用於治療hcv的固體藥物組合物

Country Status (22)

Country Link
EP (1) EP3324941A1 (zh)
JP (2) JP7133466B2 (zh)
KR (1) KR20180025317A (zh)
CN (1) CN108024964B (zh)
AU (1) AU2016296709C1 (zh)
BR (1) BR112018000982A2 (zh)
CA (1) CA2992722C (zh)
CL (1) CL2018000138A1 (zh)
CO (1) CO2018000391A2 (zh)
CR (1) CR20180088A (zh)
DO (1) DOP2018000024A (zh)
EA (1) EA201890334A1 (zh)
EC (1) ECSP18008411A (zh)
HK (1) HK1255203A1 (zh)
IL (1) IL256945B2 (zh)
MX (1) MX2018000746A (zh)
PE (1) PE20180609A1 (zh)
PH (1) PH12018500132A1 (zh)
RU (1) RU2018105849A (zh)
SG (1) SG10202002900YA (zh)
WO (1) WO2017015211A1 (zh)
ZA (1) ZA201801082B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2020210100A1 (en) * 2019-04-08 2020-10-15 Abbvie Inc. Solid pharmaceutical compositions for treating hcv

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PT2498758T (pt) * 2009-11-13 2018-10-23 Astrazeneca Uk Ltd Formulações de comprimido bicamada
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EA029145B1 (ru) * 2010-09-21 2018-02-28 Энанта Фармасьютикалз, Инк. Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
PL2968301T3 (pl) * 2013-03-14 2017-09-29 Abbvie Inc. Kombinacja dwóch środków przeciwwirusowych do leczenia zapalenia wątroby typu C
EA201890160A1 (ru) * 2015-06-26 2018-06-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с

Also Published As

Publication number Publication date
EP3324941A1 (en) 2018-05-30
AU2016296709C1 (en) 2022-02-24
IL256945B2 (en) 2023-10-01
IL256945B1 (en) 2023-06-01
BR112018000982A2 (pt) 2018-09-11
SG10202002900YA (en) 2020-05-28
CA2992722C (en) 2023-10-17
ECSP18008411A (es) 2018-04-30
CO2018000391A2 (es) 2018-06-12
CN108024964A (zh) 2018-05-11
RU2018105849A3 (zh) 2019-12-13
AU2016296709B2 (en) 2021-11-11
WO2017015211A1 (en) 2017-01-26
JP7133466B2 (ja) 2022-09-08
RU2018105849A (ru) 2019-08-19
DOP2018000024A (es) 2018-04-15
PH12018500132A1 (en) 2018-07-23
IL256945A (en) 2018-03-29
CA2992722A1 (en) 2017-01-26
PE20180609A1 (es) 2018-04-09
JP7472199B2 (ja) 2024-04-22
MX2018000746A (es) 2018-08-15
JP2022141719A (ja) 2022-09-29
CR20180088A (es) 2018-05-24
CN108024964B (zh) 2022-05-03
JP2018520185A (ja) 2018-07-26
AU2016296709A1 (en) 2018-02-08
EA201890334A1 (ru) 2018-06-29
CL2018000138A1 (es) 2018-07-13
KR20180025317A (ko) 2018-03-08
ZA201801082B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical preparations for combination therapy
IL268316B (en) Pharmaceutical preparations for combined treatment
HK1253720A1 (zh) 用於麻醉應用的藥物組合物
GB201608323D0 (en) Pharmaceutical compositions
HK1254573A1 (zh) 包含苯基氨基嘧啶衍生物的藥物組合物
GB201521462D0 (en) Pharmaceutical composition
HK1250627A1 (zh) 用於治療hcv的固體藥物組合物
HK1250491A1 (zh) 穩定化的醫藥組合物
HK1245073A1 (zh) 藥物組合物
GB201515310D0 (en) Pharmaceutical composition
ZA201703115B (en) Long acting pharmaceutical compositions for hepatitis c
HK1255203A1 (zh) 用於治療hcv的固體藥物組合物
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
ZA201705782B (en) Pharmaceutical compositions
ZA201705783B (en) Pharmaceutical compositions
GB201700831D0 (en) Pharmaceutical compositions
PT3319596T (pt) Composições farmacêuticas
GB201608393D0 (en) Solid pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition
GB201520762D0 (en) Novel pharmaceutical compositions
GB201506598D0 (en) Pharmaceutical compositions
GB201516183D0 (en) Novel pharmaceutical composition